| Not Yet Recruiting | Alpha Radiation Emitters Device (DaRT) for the Treatment of Locally Recurrent Prostate Cancer NCT07290998 | Alpha Tau Medical LTD. | N/A |
| Recruiting | Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro) NCT07365423 | Swiss Cancer Institute | Phase 2 |
| Recruiting | Trial of pTVG-HP+Nivo+Targeted Ablation of Resistant Lesions in Non-Castrate RecurrentOMPC NCT07090148 | University of Wisconsin, Madison | Phase 1 |
| Not Yet Recruiting | Determining Patterns In Trial Experiences of Recurrent Prostate Cancer Patients NCT06070272 | Power Life Sciences Inc. | — |
| Recruiting | Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen NCT06378866 | Mayo Clinic | Phase 2 |
| Recruiting | Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Ther NCT06096870 | National Cancer Institute (NCI) | Phase 2 |
| Active Not Recruiting | Trial of Ultrahypofractionated Focal Salvage Radiotherapy for Isolated Prostate Bed Recurrence After Radical P NCT05746806 | Insel Gruppe AG, University Hospital Bern | N/A |
| Unknown | SCAP vs HIFU for Recurrent Prostate Cancer After Radiation Therapy NCT05044754 | University Hospital Virgen de las Nieves | — |
| Recruiting | Tumor Microenvironment Analysis of Prostate Cancer Metastasis NCT05304858 | Columbia University | — |
| Active Not Recruiting | Study of ADXS-504 Immunotherapy for Recurrent Prostate Cancer NCT05077098 | Mark Stein | Phase 1 |
| Recruiting | Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-direc NCT04787744 | VA Office of Research and Development | Phase 2 / Phase 3 |
| Recruiting | Salvage Cryotherapy for Recurrent Prostate Cancer After Radiation Therapy NCT04891536 | Ignacio Puche Sanz | N/A |
| Completed | Safety and Efficacy of [18F]PSMA-1007 Injection in Suspected Persistent or Recurrent Prostate Cancer. NCT04644822 | Centre for Probe Development and Commercialization | Phase 3 |
| Completed | Nivolumab in Biochemically Recurrent dMMR Prostate Cancer NCT04019964 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Recruiting | PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores NCT03495427 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 / Phase 3 |
| Unknown | Impact of Atorvastatin on Prostate Cancer Progression During ADT NCT04026230 | Tampere University Hospital | Phase 3 |
| Completed | Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy NCT03496805 | Wake Forest University Health Sciences | Phase 2 |
| Unknown | PSMA-PET Registry for Recurrent Prostate Cancer NCT03718260 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | N/A |
| Completed | Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Ge NCT03602079 | Klus Pharma Inc. | Phase 1 / Phase 2 |
| Recruiting | Partial Prostate Salvage High Dose Rate Brachytherapy NCT03246802 | British Columbia Cancer Agency | N/A |
| Recruiting | Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System NCT03067051 | SpectraCure AB | Phase 1 / Phase 2 |
| Completed | Magnetic Resonance Guided Focal Stereotactic Body Radiation Therapy for Localized Prostate Cancer NCT02163317 | Case Comprehensive Cancer Center | N/A |
| Withdrawn | Carbon-11 Acetate and Fluorine F 18 Sodium Fluoride PET as a Biomarker of Treatment Response in Patients With NCT02169063 | University of Washington | N/A |
| Completed | Enzalutamide Versus Standard Androgen Deprivation Therapy for the Treatment Hormone Sensitive Prostate Cancer NCT02278185 | University of Colorado, Denver | Phase 2 |
| Completed | The Immuno-Response to Primary Cryotherapy for the Treatment of Prostate Cancer NCT02250014 | University of Colorado, Denver | Phase 1 |
| Completed | Phenelzine Sulfate in Treating Patients With Non-metastatic Recurrent Prostate Cancer NCT02217709 | University of Southern California | Phase 2 |
| Withdrawn | Vigorous or Moderate Exercise in Enhancing Active Surveillance in Patients With Localized Prostate Cancer NCT02179762 | Case Comprehensive Cancer Center | N/A |
| Completed | Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer NCT02184533 | Stanford University | Phase 1 |
| Completed | LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate C NCT02058706 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Active Not Recruiting | Enzalutamide, Radiation Therapy and Hormone Therapy in Treating Patients With Intermediate or High-Risk Prosta NCT02023463 | Thomas Jefferson University | Phase 1 |
| Unknown | Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer NCT02049190 | Arno Therapeutics | Phase 1 / Phase 2 |
| Unknown | Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metasta NCT01949337 | Alliance for Clinical Trials in Oncology | Phase 3 |
| Completed | Effect of Quercetin on Green Tea Polyphenol Uptake in Prostate Tissue From Patients With Prostate Cancer Under NCT01912820 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Completed | Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer NCT02012296 | University of Chicago | Phase 1 / Phase 2 |
| Completed | Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recur NCT01967862 | City of Hope Medical Center | N/A |
| Active Not Recruiting | Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer After Undergoing Surgery NCT01923506 | City of Hope Medical Center | Phase 1 |
| Completed | FACBC for Recurrent Prostate Cancer NCT01808222 | David M. Schuster, MD | Phase 2 |
| Terminated | Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer NCT01866423 | University of Southern California | Phase 2 |
| Completed | Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer NCT01848067 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 / Phase 2 |
| Terminated | Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cance NCT01913015 | OHSU Knight Cancer Institute | Phase 1 |
| Terminated | Cabozantinib in Men With Castration-Resistant Prostate Cancer NCT01703065 | University of Washington | Phase 2 |
| Completed | Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate NCT01807065 | City of Hope Medical Center | Phase 2 |
| Completed | Intensive Diet and Exercise or Standard of Care in Improving Physical Function and Quality of Life in Patients NCT02050906 | Ohio State University Comprehensive Cancer Center | N/A |
| Completed | Brachytherapy for Recurrent Prostate Cancer NCT01956058 | Centre Georges Francois Leclerc | Phase 2 |
| Completed | Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer NCT01812668 | Barbara Ann Karmanos Cancer Institute | N/A |
| Active Not Recruiting | Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With NCT01802346 | University of Southern California | N/A |
| Completed | Bipolar Androgen-based Therapy for Prostate Cancer (BAT) NCT01750398 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 2 |
| Active Not Recruiting | High-Dose Rate Brachytherapy and Stereotactic Body Radiation Therapy in Treating Patients With Prostate Cancer NCT01655836 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 |
| Unknown | Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resi NCT01685125 | University of Southern California | Phase 2 |
| Completed | High-Dose Stereotactic Radiation for Prostate Cancer NCT01664130 | Case Comprehensive Cancer Center | N/A |
| Terminated | Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated NCT01469338 | University of Southern California | Phase 2 |
| Completed | Magnetic Resonance Imaging in Measuring the Effect of Cabozantinib in Patients With Castrate Resistant Prostat NCT01599793 | University of Chicago | Phase 2 |
| Withdrawn | Atorvastatin Calcium in Preventing Metabolic Syndrome in Prostate Cancer Patients Receiving Androgen-Deprivati NCT01555632 | University of Nebraska | N/A |
| Withdrawn | Internal Radiation Therapy in Treating Patients With Low-Risk Prostate Cancer NCT01859689 | Jonsson Comprehensive Cancer Center | Phase 2 |
| Completed | Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resis NCT01498978 | OHSU Knight Cancer Institute | Phase 2 |
| Terminated | Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer NCT01174199 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Linsitinib in Treating Patients With Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer NCT01533246 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Metformin Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery NCT01433913 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer NCT01468532 | Barbara Ann Karmanos Cancer Institute | Phase 1 / Phase 2 |
| Completed | Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer NCT01054079 | Wake Forest University Health Sciences | Phase 2 |
| Terminated | Genistein in Treating Patients With Prostate Cancer NCT01126879 | Northwestern University | Phase 2 |
| Completed | Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Tre NCT01270880 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Terminated | Saracatinib in Treating Patients With Prostate Cancer NCT01267266 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Docetaxel Plus Lycopene in Castration Resistant, Chemotherapy-Naïve Prostate Cancer Patients NCT01882985 | University of California, Irvine | Phase 2 |
| Completed | Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Ca NCT01240629 | University of Southern California | Phase 1 / Phase 2 |
| Completed | Sulforaphane in Treating Patients With Recurrent Prostate Cancer NCT01228084 | OHSU Knight Cancer Institute | Phase 2 |
| Completed | Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel NCT01260688 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate Cancer NCT01200810 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors NCT01155258 | University of Southern California | Phase 1 |
| Terminated | Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Can NCT01093183 | University of Nebraska | Phase 1 / Phase 2 |
| Completed | Whole Body Fluorine F 18 Sodium Fluoride PET/CT Scan and Whole Body MRI in Finding Bone Metastases in Patients NCT00956163 | National Cancer Institute (NCI) | EARLY_Phase 1 |
| Completed | Soy Isoflavones in Treating Patients With Recurrent Prostate Cancer or Rising Prostate-Specific Antigen NCT01682941 | Ohio State University Comprehensive Cancer Center | N/A |
| Terminated | Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients NCT00879619 | John P. Fruehauf | Phase 1 / Phase 2 |
| Unknown | CyberKnife Radiosurgery for Locally Recurrent Prostate CA NCT00851916 | CyberKnife Centers of San Diego | Phase 2 |
| Unknown | A Multicenter Clinical Study of the Sonablate®450 for the TreAtment of Locally Recurrent Prostate Cancer With NCT00772317 | SonaCare Medical | N/A |
| Completed | Phase II Study of Adenovirus/PSA Vaccine in Men With Recurrent Prostate Cancer After Local Therapy APP21 NCT00583752 | David M Lubaroff | Phase 2 |
| Completed | Safety and Efficacy of POMx Capsules in Men With Recurrent Prostate Cancer: An 18-Month Study NCT01220817 | POM Wonderful LLC | Phase 2 |
| Terminated | Hormone Therapy and Temsirolimus in Treating Patients With Relapsed Prostate Cancer NCT00512668 | National Cancer Institute (NCI) | Phase 1 |
| Completed | AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy NCT00513071 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Trial of Dasatinib (Sprycel®) in Subjects With Hormone-refractory Prostate Cancer NCT00570700 | University of California, Irvine | Phase 2 |
| Completed | Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy NCT01656304 | Barbara Ann Karmanos Cancer Institute | Phase 2 |
| Terminated | Salvage Cryotherapy in Recurrent Prostate Cancer NCT00824928 | University of Colorado, Denver | — |
| Completed | Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy NCT00337077 | National Cancer Institute (NCI) | Phase 2 |
| Completed | MRI-Guided Biopsy of Recurrent Prostate Cancer After Radiotherapy NCT00775866 | University Health Network, Toronto | N/A |
| Completed | Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer NCT01338792 | University of Southern California | Phase 2 |
| Completed | Pazopanib Hydrochloride After Leuprolide Acetate or Goserelin Acetate in Treating Patients With Relapsed Prost NCT00454571 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy NCT00331344 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer NCT00330161 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lapatinib Ditosylate in Treating Patients With a Rising PSA Indicating Recurrent Prostate Cancer NCT00103194 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Docetaxel and Prednisone With or Without Bevacizumab in Treating Patients With Prostate Cancer That Did Not Re NCT00110214 | National Cancer Institute (NCI) | Phase 3 |
| Completed | SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel NCT00096499 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer NCT00109811 | National Cancer Institute (NCI) | Phase 2 |
| Completed | 17-AAG in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy NCT00118092 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cilengitide in Treating Patients With Metastatic Prostate Cancer NCT00103337 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Cilengitide in Treating Patients With Prostate Cancer NCT00121238 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Lapatinib in Treating Patients With Recurrent or Metastatic Prostate Cancer NCT00095667 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ixabepilone in Treating Patients With Metastatic Prostate Cancer NCT00087139 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00089362 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Naïve Prostate Cancer NCT00080899 | National Cancer Institute (NCI) | Phase 2 |
| Unknown | Peptide-specific Vaccination in HLA-A*02 Positive Patients With Biochemical Recurrence After Radical Prostatec NCT02452307 | University Hospital Tuebingen | Phase 1 / Phase 2 |
| Completed | GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-S NCT00074022 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Terminated | Perifosine in Treating Patients With Recurrent Prostate Cancer NCT00058214 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Ixabepilone Compared With Mitoxantrone and Prednisone in Treating Patients With Refractory Metastatic Prostate NCT00058084 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Combination Chemotherapy in Treating Patients With Metastatic or Unresectable Solid Tumors NCT00058253 | National Cancer Institute (NCI) | Phase 1 |
| Completed | BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy NCT00040755 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Zoledronate and BMS-275291 in Treating Patients With Prostate Cancer NCT00039104 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction NCT00030498 | National Cancer Institute (NCI) | Phase 1 |
| Completed | 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid NCT00031681 | National Cancer Institute (NCI) | Phase 1 |
| Completed | Combination Chemotherapy Plus Bevacizumab in Treating Patients With Metastatic Prostate Cancer NCT00016107 | National Cancer Institute (NCI) | Phase 2 |
| Terminated | Photodynamic Therapy With Lutetium Texaphyrin in Treating Patients With Locally Recurrent Prostate Cancer NCT00005067 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer) NCT00005039 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Docetaxel With or Without Thalidomide in Treating Patients With Metastatic Prostate Cancer NCT00020046 | National Institutes of Health Clinical Center (CC) | Phase 2 |
| Completed | Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu NCT00004074 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Ketoconazole With or Without Alendronate Sodium in Treating Patients With Metastatic Prostate Cancer NCT00019695 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer NCT00003517 | Burzynski Research Institute | Phase 2 |
| No Longer Available | Detecting Recurrent Prostate Cancer With 11C-choline Positron Emission Tomography NCT02531672 | Memorial Sloan Kettering Cancer Center | — |